Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies

  • Leukemia. 2025 Mar;39(3):765-769. doi: 10.1038/s41375-025-02515-8.
Jan Philipp Bewersdorf  #  1  2 ,  Xiaoli Mi  #  1 ,  Bin Lu  1 ,  Andrew Kuykendall  3 ,  David Sallman  3 ,  Manish Patel  4 ,  Don Stevens  5 ,  Alexander Philipovskiy  6 ,  Grerk Sutamtewagul  7 ,  Lucia Masarova  8 ,  Gina Keiffer  9 ,  Amit Verma  10 ,  Neha Bhagwat  11 ,  Min Wang  11 ,  Andrew Moore  11 ,  Joseph Rager  11 ,  Diane Heiser  11 ,  Sunhee Ro  11 ,  Wan-Jen Hong  11 ,  Omar Abdel-Wahab  12  13 ,  Eytan M Stein  14
Affiliations
  • 1. Department of Medicine; Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • 2. Yale University and Yale Cancer Center, New Haven, CT, USA.
  • 3. Moffitt Cancer Center, Tampa, FL, USA.
  • 4. Florida Cancer Specialists, Sarasota, FL, USA.
  • 5. Norton Cancer Institute, Louisville, KY, USA.
  • 6. Florida Cancer Specialists, Lake Mary, FL, USA.
  • 7. University of Iowa, Iowa City, IA, USA.
  • 8. MD Anderson Cancer Center, Houston, TX, USA.
  • 9. Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
  • 10. Montefiore Einstein Comprehensive Cancer, Bronx, NY, USA.
  • 11. Prelude Therapeutics, Wilmington, DE, USA.
  • 12. Department of Medicine; Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. [email protected].
  • 13. Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA. [email protected].
  • 14. Department of Medicine; Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. [email protected].
  • # Contributed equally.
PMID: 39856223 DOI: 10.1038/s41375-025-02515-8
Abstract

Products